Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.63 |
| ▸ | ECE1 | P42892 | 5/20 | 0.56 |
| ▸ | IL1RN | P18510 | 8/20 | 0.56 |
| ▸ | ERAP1 | Q9NZ08 | 5/20 | 0.56 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376316 | 0.96 | ERAP2 (0.67) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL29947263 | 0.95 | ACE (0.58) | ERAP2ECE1ACE | |
| SCHEMBL30511104 | 0.93 | ERAP2 (0.62) | ERAP2ECE1IL1RNERAP1KISS1R | |
| SCHEMBL20764526 | 0.93 | ERAP2 (0.70) | ERAP2ECE1IL1RNERAP1KISS1R | |
| SCHEMBL30219046 | 0.93 | ERAP2 (0.68) | ERAP2ECE1IL1RNERAP1KISS1R | |
| SCHEMBL31343242 | 0.91 | ERAP2 (0.62) | ERAP2ECE1IL1RNERAP1KISS1R | |
| SCHEMBL29354013 | 0.90 | ERAP2 (0.76) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30051545 | 0.90 | ECE1 (0.65) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL21641798 | 0.89 | KDM4E (0.62) | ERAP2ECE1ACE | |
| SCHEMBL5970454 | 0.89 | KDM4E (0.62) | ERAP2ECE1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | claimed |
| CN-118852453-A | Incretin analogue, preparation method and application thereof | 上海多米瑞生物技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | ERAP2 552/4885ECE1 1643/4885IL1RN 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.